Compare Enveric Biosciences Inc (ENVB) vs Remitly Global Inc (RELY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Remitly Global Inc — how do they compare? Enveric Biosciences Inc trades at $1.51 (market cap $6.80M), while Remitly Global Inc trades at $23.42 (market cap $4.98B). The key difference: Remitly Global Inc is far larger — about 732.4× Enveric Biosciences Inc's market cap, and Remitly Global Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enveric Biosciences Inc for 14 Days and Remitly Global Inc for 53 Days on average.
| ENVB | RELY | |
|---|---|---|
Market Cap | $6.80M | $4.98B |
Volume | 64,867 | 3,501,150 |
Sector | Health | Technology |
52-Week High | $10.80 | $26.92 |
52-Week Low | $1.27 | $12.20 |
Typical Hold Time | 14 Days | 53 Days |
Enterprise Value | -$1.49M | $4.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.495 with a 1.7% daily gain, showing technical bearish signals despite recent earnings beats. The company reported no revenue in 2025 with significant losses (-$8.77M net income), though valuation metrics appear low (EV/EBITDA 0.17, P/B 0.84). Recent news highlights patent approvals and positive preclinical data for non-hallucinogenic therapeutics.
The outlook remains speculative given the lack of revenue and substantial losses, offset by strong analyst support (75% buy rating) and promising drug development progress. Key risks include funding needs and clinical trial outcomes, while institutional sentiment appears cautiously optimistic about long-term pipeline potential.
RELY trades at $22.93, down 1.16% on the day, with a bullish technical signal from moving averages. The company shows strong fundamental momentum, with Q2 2026 revenue growth of 20% to $495 million and three consecutive quarterly EPS beats. Analyst consensus is strongly bullish with a $30.50 price target, supported by expanding profit margins and active customer growth exceeding 10 million.
Outlook remains positive given robust revenue growth and profitability expansion, but risks include competitive pressures in fintech and reliance on continued customer acquisition. The stock offers upside to analyst targets, though volatility may persist amid market shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Remitly Global Inc
Remitly Global Inc provides integrated financial services to immigrants, including helping customers send money internationally in a quick, reliable, and more cost-effective manner by leveraging digital channels. It supports cross-border transmissions across the globe. Its revenue is generated on transaction fees charged to customers and foreign exchange spreads between the foreign exchange rate offered to customers and the foreign exchange rate on the company's currency purchases.
Read more on RELY →
